Anticoagulation: Medications, Monitoring, and Complications

Anticoagulation is used to prevent and treat abnormal blood clot formation in a variety of clinical settings. It plays an important role in venous thromboembolism, pulmonary embolism, atrial fibrillation, mechanical heart valves, extracorporeal membrane oxygenation, and other conditions where thrombosis presents a significant risk.

Several classes of anticoagulants are available, each with different mechanisms, monitoring requirements, routes of administration, adverse effects, and reversal strategies.

Understanding how these medications affect coagulation is essential for recognizing their clinical uses and potential complications.

What Is Anticoagulation?

Anticoagulation refers to the use of medications that interfere with the coagulation process to reduce the formation or extension of blood clots. These medications are part of a larger group of drugs known as antithrombotic agents.

Antithrombotic medications can generally be divided into three categories:

• Anticoagulants
• Antiplatelet agents
• Thrombolytic agents

Although these medications all affect thrombosis, they work differently. Antiplatelet medications interfere primarily with platelet activation and aggregation. Anticoagulants interfere with the coagulation cascade and the formation of fibrin. Thrombolytic medications act on an existing thrombus by promoting its breakdown.

Anticoagulants generally do not directly dissolve an established blood clot. Instead, they reduce additional clot formation, limit extension of the existing thrombus, and decrease the risk of recurrent thromboembolic events.

How Blood Clots Form

Understanding anticoagulation requires a basic understanding of normal clot formation. When a blood vessel is injured, the endothelial lining is disrupted and the underlying procoagulant surface becomes exposed. Platelets quickly adhere to the damaged area, with von Willebrand factor playing an important role in platelet adhesion.

The platelets are then activated by substances such as collagen and thrombin. Activated platelets release chemical mediators that promote further platelet recruitment and aggregation.

These substances include:

• Adenosine diphosphate
• Serotonin
• Norepinephrine
• Arachidonic acid metabolites

Activated platelets also express glycoprotein IIb/IIIa receptors on their surface. Fibrinogen binds to these receptors and connects neighboring platelets, helping form the initial platelet plug.

This plug alone is relatively unstable. A more durable clot requires activation of the coagulation cascade and the formation of fibrin.

The Coagulation Cascade

The coagulation cascade consists of multiple clotting factors that interact through the intrinsic and extrinsic pathways. These pathways ultimately converge with activation of factor X.

Activated factor X works with factor V to promote the conversion of prothrombin, also called factor II, into thrombin. Thrombin then converts fibrinogen into fibrin.

Fibrin forms a structural network that strengthens and stabilizes the developing blood clot. Additional coagulation activity further reinforces the thrombus.

Many anticoagulant medications work by interfering with critical steps in this process. Common targets include thrombin, factor Xa, and the vitamin K-dependent clotting factors.

Venous Thromboembolism

One of the most important uses of anticoagulation is the prevention and treatment of venous thromboembolism.

Venous thromboembolism, or VTE, includes:

• Deep venous thrombosis
• Pulmonary embolism

Deep venous thrombosis occurs when a thrombus develops within a deep vein, most commonly in the lower extremities. Part of the thrombus may detach from the vessel wall and travel through the venous circulation.

The embolus eventually reaches the right side of the heart and can enter the pulmonary circulation, where it may obstruct a pulmonary artery. This produces a pulmonary embolism.

Because a significant pulmonary embolism may cause rapid respiratory and cardiovascular deterioration, anticoagulation is commonly started promptly when VTE is strongly suspected unless an important contraindication is present.

Prevention of Venous Thromboembolism

Preventing VTE is especially important in hospitalized patients. Immobility, surgery, critical illness, and numerous medical conditions can increase the likelihood of venous thrombosis.

Risk varies considerably according to the patient’s underlying condition and degree of immobility. Patients undergoing minor procedures may have a relatively low risk, while major orthopedic procedures involving the hip or knee are associated with substantially greater risk.

Other patients with increased VTE risk may include those with:

• Acute spinal cord injury
• Myocardial infarction
• Ischemic stroke
• Obesity
• Heart failure
• Renal failure
• Hypercoagulable disorders
• Previous VTE
• Critical illness
• Prolonged immobility

Pharmacologic Prophylaxis

Patients at increased risk who do not have an excessive risk of bleeding may receive pharmacologic VTE prophylaxis. Common preventive anticoagulants include low-dose unfractionated heparin, low-molecular-weight heparin, and fondaparinux.

Low-molecular-weight heparins commonly used for prophylaxis include enoxaparin and dalteparin. Although pharmacologic prophylaxis reduces the likelihood of VTE, it does not completely eliminate the risk.

Mechanical Prophylaxis

Mechanical methods can also be used to decrease venous stasis.

Examples include:

• Early ambulation
• Graduated compression stockings
• Intermittent pneumatic compression devices
• Venous foot pumps

Note: Mechanical prophylaxis can be especially valuable when anticoagulant medications cannot be administered because of bleeding risk.

Initiating Anticoagulation for VTE

When VTE is strongly suspected, anticoagulation may be started before definitive diagnostic confirmation if the risk of withholding therapy is considered greater than the bleeding risk. Treatment may then continue while diagnostic testing is performed.

Important contraindications can include active or recent significant bleeding, recent serious head trauma, and other conditions associated with a high risk of hemorrhage. The purpose of early therapy is to reduce propagation of the existing thrombus and decrease the likelihood of additional embolic events.

In patients with pulmonary embolism, establishing adequate anticoagulation promptly is particularly important because recurrent embolization may substantially worsen the patient’s condition.

Unfractionated Heparin

Unfractionated heparin is one of the traditional anticoagulants used in clinical medicine. It produces anticoagulation primarily by interacting with antithrombin. The heparin-antithrombin complex inhibits several activated clotting factors, particularly thrombin and factor Xa.

Unfractionated heparin has approximately equivalent activity against factor Xa and thrombin. By reducing thrombin activity, heparin decreases conversion of fibrinogen to fibrin and limits the formation of a stable fibrin clot.

Administration

For treatment of serious thromboembolic disease, unfractionated heparin is commonly administered as an intravenous bolus followed by continuous intravenous infusion. The dose can then be adjusted according to coagulation testing and a treatment protocol.

Lower doses may be given subcutaneously for VTE prophylaxis. An important advantage of intravenous unfractionated heparin is its rapid onset. The anticoagulant effect can also be adjusted relatively quickly by changing or stopping the infusion.

Monitoring Unfractionated Heparin

Activated partial thromboplastin time, or aPTT, has traditionally been used to monitor unfractionated heparin therapy.

The dose is adjusted according to the relationship between the patient’s aPTT and the laboratory control value. Therapeutic anticoagulation may involve maintaining the aPTT above approximately 1.5 times the control value, although exact targets depend on the protocol being used.

Frequent monitoring may be required when therapy begins or when the infusion rate is adjusted. The response to unfractionated heparin can vary considerably between patients because the medication binds to plasma proteins, endothelial cells, and other substances. This variability is one reason laboratory monitoring is necessary.

Low-Molecular-Weight Heparin

Low-molecular-weight heparins are smaller fragments derived from heparin.

Examples include:

• Enoxaparin
• Dalteparin

Low-molecular-weight heparins have proportionally greater activity against factor Xa than against thrombin. For example, dalteparin has an approximate antifactor Xa to antifactor IIa ratio of 2:1, while enoxaparin has a ratio of approximately 3.8:1.

Because factor Xa participates in thrombin generation, reducing factor Xa activity decreases the amount of thrombin produced later in the coagulation process.

Advantages of LMWH

Low-molecular-weight heparin has more predictable bioavailability than unfractionated heparin. This allows reliable subcutaneous administration for many indications. Routine aPTT monitoring is generally unnecessary.

If laboratory assessment is required, antifactor Xa activity may be measured. This is usually reserved for selected patients, such as those with significant renal impairment or unusual body weight.

LMWH has become widely used for VTE prevention and treatment because of its predictable pharmacologic effect and convenient dosing.

Adverse Effects of Heparin

Bleeding is the major adverse effect of both unfractionated heparin and low-molecular-weight heparin.

Other complications may include:

• Hematoma
• Thrombocytopenia
• Hyperkalemia
• Osteoporosis with prolonged treatment
• Elevated liver enzymes

Note: One particularly important complication is heparin-induced thrombocytopenia.

Heparin-Induced Thrombocytopenia

heparin-induced thrombocytopenia, or HIT, is a clinically important complication of heparin exposure. Two forms are generally described.

HIT Type 1

HIT type 1 is generally characterized by an early and relatively mild decrease in the platelet count. It is usually transient and is less clinically significant than the immune-mediated form.

HIT Type 2

HIT type 2 is an immune-mediated condition involving antibodies associated with platelet factor 4. Rather than simply causing a bleeding tendency from thrombocytopenia, HIT type 2 can activate platelets and promote thrombosis.

This means that a patient may have a falling platelet count while simultaneously developing serious thrombotic complications.

Possible consequences include:

• Pulmonary embolism
• Myocardial infarction
• Stroke
• Limb ischemia
• Skin necrosis
• Renal thrombosis
• Hepatic thrombosis
• Gangrene

A platelet count that falls by more than approximately 50% from baseline should raise concern, particularly when the decrease occurs several days after heparin therapy begins.

Patients previously exposed to heparin may develop HIT more quickly if circulating heparin-dependent antibodies are already present. If clinically significant HIT is suspected, heparin should be discontinued.

LMWH should not simply be substituted because cross-reactivity can occur. Alternative anticoagulants may include agents such as argatroban or bivalirudin.

Reversal of Heparin

Protamine sulfate can be used to reverse unfractionated heparin. Protamine is positively charged and binds to negatively charged heparin, forming a complex that no longer has significant anticoagulant activity.

Approximately 1 mg of protamine may neutralize 100 units of heparin, although the required amount depends on how much heparin remains active in the circulation.

Protamine should be given slowly by the intravenous route. Rapid administration may cause adverse effects such as:

• Hypotension
• Bradycardia
• Dyspnea

Note: Allergic reactions can also occur. Excessive protamine administration can itself impair coagulation and increase the risk of bleeding. Protamine is less effective at reversing LMWH because it does not completely neutralize the medication’s antifactor Xa activity.

Fondaparinux

Fondaparinux is an anticoagulant that selectively inhibits factor Xa through an antithrombin-dependent mechanism. It can be used in certain patients for prevention or treatment of venous thromboembolism.

Because its mechanism differs somewhat from unfractionated heparin, fondaparinux may also be considered in selected clinical situations where heparin presents difficulties. As with other anticoagulants, bleeding remains an important concern.

Direct Thrombin Inhibitors

Direct thrombin inhibitors act directly on thrombin without requiring antithrombin as a cofactor.

Parenteral medications in this class include:

• Argatroban
• Bivalirudin
• Desirudin
• Lepirudin

Dabigatran is an orally administered direct thrombin inhibitor. These medications can inhibit thrombin associated with circulating blood as well as thrombin associated with an established fibrin clot.

Direct thrombin inhibitors may be especially useful when heparin cannot be administered, including certain cases of heparin-induced thrombocytopenia.

Monitoring

Parenteral direct thrombin inhibitors may be monitored using the aPTT. A therapeutic target may be approximately 1.5 to 2.5 times the upper limit of the control value, depending on the specific medication and treatment protocol.

Hemorrhage is the primary adverse effect. Allergic reactions can also occur and may include bronchospasm, stridor, or dyspnea.

Warfarin

Warfarin is an oral vitamin K antagonist that has been used extensively for long-term anticoagulation.

It may be used for conditions including:

• Venous thrombosis
• Pulmonary embolism
• Atrial fibrillation
• Mechanical heart valves
• Selected thromboembolic complications after myocardial infarction

Note: Warfarin interferes with hepatic production of the vitamin K-dependent clotting factors II, VII, IX, and X. It also decreases proteins C and S, which function as natural anticoagulants.

Delayed Effect of Warfarin

Warfarin does not produce immediate anticoagulation because clotting factors already circulating in the bloodstream must decline before the full effect becomes apparent.

Changes in coagulation may begin within approximately 12 to 24 hours, but complete antithrombotic activity can require several days.

For this reason, patients requiring immediate anticoagulation may initially receive a faster-acting parenteral anticoagulant while warfarin therapy is started.

The medications are overlapped until an adequate therapeutic anticoagulant effect has been achieved. This approach also helps protect against the temporary hypercoagulable state that can occur early in warfarin therapy.

Warfarin and the INR

Warfarin therapy is monitored using the international normalized ratio, or INR. The INR is based on the prothrombin time but provides a standardized value that reduces variability caused by different laboratory reagents.

A person who is not therapeutically anticoagulated generally has an INR close to normal laboratory values, often approximately 0.9 to 1.3. For many conditions treated with warfarin, the target INR is approximately 2 to 3.

An INR below the therapeutic range may indicate inadequate anticoagulation and greater thrombotic risk. An excessively elevated INR increases the likelihood of bleeding. Because warfarin has a relatively narrow therapeutic range, regular laboratory monitoring is important.

Complications of Warfarin

Hemorrhage is the major complication of warfarin therapy. Bleeding can range from minor bruising to life-threatening internal hemorrhage.

Possible manifestations include:

• Petechiae
• Purpura
• Gastrointestinal bleeding
• Hematuria
• Hemoptysis
• Hematemesis
• Epistaxis
• Gingival bleeding

Warfarin-Associated Skin Necrosis

Early warfarin therapy can temporarily promote a hypercoagulable state. Proteins C and S have relatively short half-lives and may decrease more rapidly than several procoagulant clotting factors.

This temporary imbalance may promote thrombosis in small vessels and contribute to warfarin-associated skin necrosis. Overlapping warfarin with a rapidly acting anticoagulant during initial therapy can reduce this risk when immediate anticoagulation is required.

Purple Toe Syndrome

Purple toe syndrome is another uncommon complication associated with warfarin. It is characterized by painful or purplish discoloration of the toes and may result from cholesterol-rich microemboli. The condition may appear several weeks after warfarin therapy begins.

Reversal of Warfarin

Vitamin K₁, also known as phytonadione, can be used to reverse the anticoagulant effect of warfarin. In severe or life-threatening bleeding, more rapid replacement of clotting factors may be necessary.

Four-factor prothrombin complex concentrate contains factors II, VII, IX, and X and can be administered along with vitamin K for urgent reversal.

Compared with plasma, prothrombin complex concentrate requires a much smaller infusion volume and does not require blood typing or thawing. Reversing anticoagulation must still be approached carefully because restoring coagulation can increase the risk of thrombosis.

Warfarin Interactions

Warfarin is affected by numerous dietary, pharmacologic, physiologic, and genetic factors. Vitamin K intake is particularly important.

A large increase in vitamin K intake may reduce the anticoagulant effect of warfarin and lower the INR. A sudden decrease in vitamin K intake may increase the INR and bleeding risk.

Patients taking warfarin are therefore generally encouraged to maintain relatively consistent dietary habits rather than making major changes in vitamin K intake. Many medications also interact with warfarin.

Some increase its effect by altering metabolism, while others decrease its effectiveness or influence bleeding risk through separate mechanisms. Close INR monitoring is important when medications are added, discontinued, or significantly changed. Genetic differences involving enzymes such as CYP2C9 and proteins related to vitamin K metabolism also contribute to variability in warfarin response.

Direct Oral Anticoagulants

Several newer oral anticoagulants provide alternatives to warfarin. These include the direct thrombin inhibitor dabigatran and direct factor Xa inhibitors such as:

• Rivaroxaban
• Apixaban
• Edoxaban

Note: These medications have relatively rapid onset and generally do not require routine INR monitoring. They also avoid many of the dietary limitations associated with warfarin.

Dabigatran

Dabigatran directly inhibits thrombin. It is administered as dabigatran etexilate, which is converted to the active medication after administration.

Renal elimination is important, so kidney function must be considered when evaluating its use and dosage. For VTE treatment, parenteral anticoagulation is generally given before transitioning to dabigatran.

Rivaroxaban and Apixaban

Rivaroxaban and apixaban directly inhibit factor Xa. Unlike dabigatran and edoxaban, these medications may be used for initial VTE treatment without preceding parenteral anticoagulation.

Renal function and medication interactions remain important considerations. Drugs affecting CYP3A4 and P-glycoprotein pathways may alter the effect of some factor Xa inhibitors.

Duration of Anticoagulation

The required duration of anticoagulation depends largely on the reason the thrombosis occurred and the patient’s ongoing risk.

A provoked VTE occurs in association with an identifiable temporary risk factor. For example, a DVT occurring after major hip surgery and prolonged immobilization may require approximately three months of anticoagulation.

Longer treatment may be considered for patients with persistent risk factors. Recurrent unprovoked VTE and thromboembolism associated with active cancer may require prolonged or long-term anticoagulation. The risk of recurrent thrombosis must always be weighed against the risk of bleeding from continued therapy.

Pulmonary Embolism and Anticoagulation

Anticoagulation is a major component of pulmonary embolism treatment. Unfractionated heparin, LMWH, or selected oral anticoagulants may be used depending on the patient’s condition and the chosen treatment strategy.

The purpose of anticoagulation is to prevent further clot propagation and recurrent embolization while the body gradually removes the existing thrombus. Supportive therapy may include supplemental oxygen for hypoxemia, analgesia, intravenous fluids, and vasopressor therapy in patients with hemodynamic compromise.

Thrombolysis in Pulmonary Embolism

Anticoagulation and thrombolysis should not be confused. Anticoagulants primarily prevent additional clot formation, while thrombolytic medications actively promote degradation of an existing thrombus.

Thrombolytic therapy may be considered in patients with massive pulmonary embolism accompanied by severe cardiovascular instability.

Signs of hemodynamic instability may include:

• Systolic blood pressure below 90 mm Hg
• A decrease in systolic pressure of at least 40 mm Hg lasting longer than 15 minutes
• Vasopressor requirement
• Acute right-heart failure
• Shock

Note: When thrombolysis is contraindicated or ineffective, catheter-based or surgical pulmonary embolectomy may be considered in appropriate centers.

Anticoagulation During ECMO

Anticoagulation is also required during extracorporeal membrane oxygenation because circulating blood continuously contacts artificial surfaces. These surfaces include the tubing, pump, membrane oxygenator, and other components of the extracorporeal circuit.

Contact with artificial materials activates coagulation and increases the risk of thrombus formation.

Without adequate anticoagulation, clot can develop within the circuit, increasing resistance, obstructing blood flow, reducing oxygenator function, and potentially requiring replacement of circuit components.

Heparin During ECMO

Continuous unfractionated heparin infusion has traditionally been used for ECMO anticoagulation. Its activity depends on antithrombin.

If antithrombin activity is inadequate, the patient may appear resistant to heparin. Increasing the heparin dose may fail to produce the expected anticoagulant response because sufficient antithrombin is not available.

Unexpected clot formation within the ECMO circuit or difficulty achieving anticoagulation targets should therefore raise concern about inadequate antithrombin activity.

Monitoring ECMO Anticoagulation

The activated clotting time, or ACT, has traditionally been used as a rapid bedside measurement of anticoagulation during ECMO. Therapeutic ranges vary according to the protocol and clinical situation. Values such as approximately 160 to 180 seconds or 180 to 200 seconds have been described.

ACT is useful because it can be obtained rapidly at the bedside, but it does not completely describe coagulation during ECMO.

Additional laboratory measurements may include:

• Anti-factor Xa activity
• Antithrombin activity
• Platelet count
• Other coagulation studies

Note: Anti-factor Xa activity can provide a more direct assessment of heparin activity, while antithrombin measurement may help identify heparin resistance.

Circuit Monitoring During ECMO

Laboratory values are only part of ECMO anticoagulation management. The extracorporeal circuit must also be inspected for visible clot formation. Pressure measurements before and after the membrane oxygenator provide important information about circuit resistance.

Clot accumulation within the oxygenator can increase resistance and produce rising premembrane pressures. These changes may provide early evidence that circuit thrombosis is developing even before complete circuit failure occurs.

Bleeding During ECMO

Bleeding is one of the most important complications of ECMO anticoagulation.

Hemorrhage may occur from:

• Cannulation sites
• Surgical wounds
• The oropharynx
• Pleural spaces
• Intravenous access sites
• Other invasive procedure sites

Note: The need for systemic anticoagulation combined with critical illness and multiple invasive procedures makes bleeding surveillance particularly important. Management may require adjustment of anticoagulation and replacement of blood components.

Intracranial Hemorrhage During ECMO

Intracranial hemorrhage is one of the most serious complications associated with ECMO, particularly in neonates.

Systemic anticoagulation increases bleeding risk while neonatal cerebral circulation may already be vulnerable because of prematurity, previous hypoxemia, acidosis, blood pressure changes, and altered cerebral blood flow.

Serial head ultrasound examinations may be used to detect intracranial bleeding during neonatal ECMO. Blood pressure must also be carefully controlled because severe hypertension combined with anticoagulation may increase the risk of cerebral hemorrhage.

The challenge is to maintain sufficient anticoagulation to protect the extracorporeal circuit without creating an unacceptable risk of neurological bleeding.

Anticoagulation When ECMO Flow Decreases

Thrombotic risk may change as ECMO flow is reduced during the weaning process. Lower circuit flow means blood moves more slowly through the extracorporeal system. Prolonged low-flow states may encourage blood stagnation and clot formation.

Anticoagulation and careful circuit surveillance therefore remain important even as the patient’s underlying cardiopulmonary function improves.

Coagulation Testing

Several laboratory tests are important when evaluating patients receiving anticoagulants.

Prothrombin Time

Prothrombin time, or PT, primarily evaluates the extrinsic and common coagulation pathways. It is particularly important in the evaluation of patients receiving warfarin. Because PT results vary according to laboratory reagents, the INR is used to standardize the measurement.

Partial Thromboplastin Time

Partial thromboplastin time evaluates the intrinsic and common coagulation pathways. Activated PTT is commonly used to monitor intravenous unfractionated heparin and certain direct thrombin inhibitors.

Anti-Factor Xa Activity

Anti-factor Xa testing may be used in selected patients receiving LMWH or when monitoring heparin in specialized settings such as ECMO. Routine antifactor Xa monitoring is not required for most patients receiving standard LMWH therapy.

Anticoagulation Before Procedures

Coagulation status is particularly important when a patient is scheduled for a procedure associated with bleeding risk. Bronchoscopy with biopsy or tissue sampling is one example.

The clinician should consider the anticoagulant being used, its mechanism, the most relevant laboratory values, the patient’s renal function when applicable, and the potential consequences of temporarily interrupting therapy.

The risk of bleeding must be weighed against the risk of recurrent thrombosis or embolism if anticoagulation is withheld.

When Anticoagulation Cannot Be Used

Some patients have such a high risk of bleeding that anticoagulation cannot safely be administered. In selected patients with venous thromboembolic disease, an inferior vena cava filter may be considered.

An IVC filter is positioned within the vena cava to capture large venous thrombi before they can reach the pulmonary circulation.

Potential indications include contraindications to anticoagulation and selected cases of recurrent pulmonary embolism despite adequate therapy.

Although filters can reduce the immediate risk of pulmonary embolization, they may increase the long-term risk of recurrent DVT. For this reason, they do not simply replace anticoagulation in patients who can safely receive anticoagulant therapy.

Balancing Thrombosis and Bleeding

The central challenge of anticoagulation is maintaining an appropriate balance between thrombosis and hemorrhage. Insufficient anticoagulation can allow existing thrombi to grow and may permit new thrombosis or recurrent embolization.

Excessive anticoagulation can produce significant or life-threatening bleeding. Safe treatment requires consideration of several factors, including:

• The indication for anticoagulation
• Severity of thrombotic risk
• Bleeding risk
• Renal function
• Medication interactions
• Laboratory results
• Route of administration
• Reversal options
• Duration of therapy
• Changes in the patient’s clinical condition

Note: No single anticoagulant is appropriate for every patient.

Role of the Respiratory Therapist

Respiratory therapists frequently care for patients receiving anticoagulation, particularly those with pulmonary embolism, critical illness, mechanical ventilation, ECMO, and cardiopulmonary disease. Although prescribing and managing anticoagulant dosing generally involves the medical team, respiratory therapists should understand the implications of anticoagulation during respiratory care.

For example, an anticoagulated patient may have increased bleeding risk during airway suctioning, bronchoscopy, arterial puncture, invasive line placement, or other procedures.

Unexpected hemoptysis, bleeding from airway devices, excessive bruising, persistent bleeding from an arterial puncture site, falling hemoglobin, or evidence of circuit thrombosis during ECMO should be recognized and reported promptly.

Knowledge of the medication being used can also help the respiratory therapist interpret relevant coagulation studies and understand why certain procedures may need to be delayed or modified.

Anticoagulation Practice Questions

1. What is anticoagulation?
Anticoagulation is the use of medications to reduce blood clot formation and prevent existing clots from growing or causing additional thromboembolic events.

2. What are the three major categories of antithrombotic medications?
The three major categories are anticoagulants, antiplatelet agents, and thrombolytic agents.

3. What is the primary action of anticoagulant medications?
Anticoagulants interfere with the coagulation cascade to reduce fibrin formation and limit further clot development.

4. What is the primary action of antiplatelet medications?
Antiplatelet medications interfere with platelet activation and aggregation during the early stages of clot formation.

5. What is the primary action of thrombolytic medications?
Thrombolytic medications promote the breakdown of fibrin within an established thrombus.

6. What does VTE stand for?
VTE stands for venous thromboembolism.

7. Which two conditions are included under venous thromboembolism?
Venous thromboembolism includes deep venous thrombosis (DVT) and pulmonary embolism (PE).

8. How can a deep venous thrombosis cause a pulmonary embolism?
A portion of a deep venous thrombus can dislodge, travel through the venous circulation, and obstruct a pulmonary artery.

9. Where do deep venous thrombi most commonly develop?
Deep venous thrombi most commonly develop in the deep veins of the lower extremities.

10. Why may anticoagulation be started before VTE is definitively confirmed?
Anticoagulation may be started when VTE is strongly suspected because delaying treatment can increase the risk of thrombus extension, recurrent embolism, and death.

11. What is the main goal of anticoagulation in an existing venous thrombus?
The main goal is to prevent the thrombus from extending and reduce the formation of additional thrombi and recurrent embolic events.

12. Why is VTE prophylaxis important in hospitalized patients?
Hospitalized patients often have immobility, illness, surgery, or other risk factors that increase the likelihood of venous thrombosis.

13. What are some conditions associated with an increased risk of VTE?
Risk factors include prolonged immobility, major orthopedic surgery, spinal cord injury, myocardial infarction, ischemic stroke, obesity, heart failure, renal failure, hypercoagulable disorders, and previous VTE.

14. Which anticoagulants may be used for pharmacologic VTE prophylaxis?
Low-dose unfractionated heparin, low-molecular-weight heparin, and fondaparinux may be used for pharmacologic VTE prophylaxis.

15. What are common mechanical methods used to prevent VTE?
Common methods include early ambulation, graduated compression stockings, intermittent pneumatic compression devices, and venous foot pumps.

16. When are mechanical methods of VTE prophylaxis especially useful?
Mechanical prophylaxis is especially useful when anticoagulant medications are contraindicated because of an increased risk of bleeding.

17. What is unfractionated heparin?
Unfractionated heparin is an anticoagulant that enhances the activity of antithrombin and inhibits important clotting factors, particularly thrombin and factor Xa.

18. How does heparin produce its anticoagulant effect?
Heparin binds with antithrombin and enhances its ability to inhibit thrombin, factor Xa, and other activated clotting factors.

19. How is unfractionated heparin commonly administered for acute VTE treatment?
It is commonly administered as an intravenous bolus followed by a continuous intravenous infusion.

20. Which laboratory test is commonly used to monitor unfractionated heparin?
The activated partial thromboplastin time (aPTT) is commonly used to monitor unfractionated heparin therapy.

21. What is a common therapeutic aPTT goal during unfractionated heparin therapy?
A common goal is an aPTT greater than approximately 1.5 times the control value, although specific therapeutic ranges depend on the treatment protocol.

22. What are low-molecular-weight heparins?
Low-molecular-weight heparins are smaller heparin fragments that produce predictable anticoagulation and have proportionally greater activity against factor Xa than thrombin.

23. What are two examples of low-molecular-weight heparin?
Enoxaparin and dalteparin are examples of low-molecular-weight heparin.

24. How are low-molecular-weight heparins commonly administered?
Low-molecular-weight heparins are commonly administered by subcutaneous injection once or twice daily.

25. Does low-molecular-weight heparin usually require routine aPTT monitoring?
No. Low-molecular-weight heparin generally does not require routine aPTT monitoring because its anticoagulant effect is more predictable.

26. What is the major adverse effect of unfractionated heparin and low-molecular-weight heparin?
The major adverse effect is bleeding.

27. What is heparin-induced thrombocytopenia (HIT)?
Heparin-induced thrombocytopenia is a complication of heparin therapy characterized by a fall in platelet count, with the immune-mediated form also increasing the risk of thrombosis.

28. What is HIT type 1?
HIT type 1 is an early, usually mild and transient decrease in platelet count that is generally less clinically significant.

29. What is HIT type 2?
HIT type 2 is an immune-mediated reaction involving antibodies associated with platelet factor 4 that can cause thrombocytopenia and serious thrombosis.

30. Why is HIT type 2 dangerous?
HIT type 2 can cause widespread platelet activation and thrombosis, leading to complications such as pulmonary embolism, stroke, myocardial infarction, skin necrosis, or gangrene.

31. What platelet change should raise concern for HIT type 2?
A platelet count decrease greater than approximately 50% from baseline should raise concern for HIT type 2.

32. Should low-molecular-weight heparin be substituted for unfractionated heparin in a patient with HIT?
No. Low-molecular-weight heparin should not simply replace unfractionated heparin because cross-reactivity can occur.

33. Which anticoagulants may be used as alternatives in patients with HIT?
Direct thrombin inhibitors such as argatroban and bivalirudin may be used as alternatives in patients with HIT.

34. What is the antidote for unfractionated heparin?
Protamine sulfate is the antidote used to reverse unfractionated heparin.

35. How does protamine sulfate reverse heparin?
Protamine sulfate binds to heparin and forms an inactive complex that reduces its anticoagulant effect.

36. How much protamine is commonly used to neutralize heparin?
Approximately 1 mg of protamine is used to neutralize 100 units of heparin, depending on how much active heparin remains in the circulation.

37. Why should protamine sulfate be administered slowly?
Rapid administration can cause adverse effects such as hypotension, bradycardia, dyspnea, and allergic reactions.

38. Does protamine completely reverse low-molecular-weight heparin?
No. Protamine only partially reverses the antifactor Xa activity of low-molecular-weight heparin.

39. What is fondaparinux?
Fondaparinux is an anticoagulant that selectively inhibits factor Xa through an antithrombin-dependent mechanism.

40. What are direct thrombin inhibitors?
Direct thrombin inhibitors are anticoagulants that bind directly to thrombin and reduce its ability to promote fibrin formation.

41. Do direct thrombin inhibitors require antithrombin to work?
No. Direct thrombin inhibitors act directly on thrombin without depending on antithrombin.

42. What are examples of parenteral direct thrombin inhibitors?
Examples include argatroban, bivalirudin, desirudin, and lepirudin.

43. Which direct thrombin inhibitor is administered orally?
Dabigatran is an orally administered direct thrombin inhibitor.

44. What laboratory test may be used to monitor parenteral direct thrombin inhibitors?
The activated partial thromboplastin time (aPTT) may be used to monitor parenteral direct thrombin inhibitors.

45. What is the major adverse effect of direct thrombin inhibitors?
Hemorrhage is the major adverse effect of direct thrombin inhibitors.

46. What is warfarin?
Warfarin is an oral anticoagulant that acts as a vitamin K antagonist.

47. Which clotting factors are reduced by warfarin?
Warfarin reduces hepatic synthesis of the vitamin K-dependent clotting factors II, VII, IX, and X.

48. Which natural anticoagulant proteins are also reduced by warfarin?
Warfarin also decreases proteins C and S.

49. Why does warfarin not produce an immediate anticoagulant effect?
Warfarin does not work immediately because previously formed clotting factors must decline before the full anticoagulant effect develops.

50. How long may it take for warfarin to produce full antithrombotic activity?
Full antithrombotic activity may require approximately 5 to 7 days.

51. Why is parenteral anticoagulation often overlapped with warfarin when rapid anticoagulation is needed?
Parenteral anticoagulation is overlapped with warfarin because warfarin has a delayed onset and may initially create a temporary hypercoagulable state.

52. Which laboratory value is used to monitor warfarin therapy?
The international normalized ratio (INR) is used to monitor warfarin therapy.

53. What is a common therapeutic INR range for many patients receiving warfarin?
A common therapeutic INR range is approximately 2 to 3.

54. What is the usual INR range in a person who is not therapeutically anticoagulated?
The usual INR range is approximately 0.9 to 1.3.

55. What does an excessively high INR indicate?
An excessively high INR indicates an increased risk of bleeding.

56. What can an abnormally low INR indicate in a patient receiving warfarin?
An abnormally low INR may indicate inadequate anticoagulation and an increased risk of thrombosis.

57. What is the principal adverse effect of warfarin?
The principal adverse effect of warfarin is hemorrhage.

58. What are common signs of bleeding associated with warfarin therapy?
Possible signs include bruising, petechiae, purpura, gastrointestinal bleeding, hematuria, hemoptysis, hematemesis, epistaxis, and gingival bleeding.

59. What is warfarin-associated skin necrosis?
Warfarin-associated skin necrosis is a rare complication related to a temporary hypercoagulable state that can occur early in therapy as proteins C and S decline.

60. What is purple toe syndrome?
Purple toe syndrome is a complication of warfarin characterized by purplish or mottled discoloration of the toes related to cholesterol-rich microembolization.

61. Which medication can be used to reverse the anticoagulant effect of warfarin?
Vitamin K1, also known as phytonadione, can be used to reverse warfarin.

62. What can be given with vitamin K for urgent reversal of major warfarin-associated bleeding?
Four-factor prothrombin complex concentrate can be administered with vitamin K for urgent reversal.

63. Which clotting factors are contained in four-factor prothrombin complex concentrate?
It contains clotting factors II, VII, IX, and X.

64. Why can four-factor prothrombin complex concentrate be useful during urgent warfarin reversal?
It provides rapid replacement of clotting factors with a smaller infusion volume than plasma and does not require blood typing or thawing.

65. How can increased vitamin K intake affect warfarin therapy?
Increased vitamin K intake can reduce warfarin’s anticoagulant effect and lower the INR.

66. How can a sudden decrease in vitamin K intake affect a patient taking warfarin?
A sudden decrease in vitamin K intake can increase the INR and raise the risk of bleeding.

67. Why should patients taking warfarin maintain a relatively consistent diet?
A consistent diet helps prevent large changes in vitamin K intake that could alter the anticoagulant effect of warfarin.

68. Why should the INR be monitored closely when medications are added or discontinued in a patient taking warfarin?
Many medications interact with warfarin and can increase or decrease its anticoagulant effect.

69. Which genetic factors can contribute to differences in warfarin response?
Genetic differences involving CYP2C9 and VKORC1 can contribute to variations in warfarin metabolism and sensitivity.

70. What are direct oral anticoagulants?
Direct oral anticoagulants are orally administered drugs that directly inhibit thrombin or factor Xa without requiring routine INR monitoring.

71. Which oral anticoagulant directly inhibits thrombin?
Dabigatran directly inhibits thrombin.

72. Which oral anticoagulants directly inhibit factor Xa?
Rivaroxaban, apixaban, and edoxaban directly inhibit factor Xa.

73. Which oral anticoagulants can be started for VTE treatment without preceding parenteral anticoagulation?
Rivaroxaban and apixaban can be started without preceding parenteral anticoagulation.

74. Which oral anticoagulants generally require initial parenteral anticoagulation before they are started for VTE treatment?
Dabigatran and edoxaban generally require preceding parenteral anticoagulation.

75. Why is renal function important when using dabigatran?
Dabigatran is eliminated primarily through the kidneys, so impaired renal function can affect its clearance, suitability, and dosing.

76. What is one major practical advantage of direct oral anticoagulants compared with warfarin?
Direct oral anticoagulants have a relatively rapid onset and generally do not require routine INR monitoring.

77. What are important limitations of direct oral anticoagulants?
Important limitations include bleeding risk, renal considerations, drug interactions, cost, and reversal concerns.

78. How long is anticoagulation commonly continued after a provoked VTE such as one following hip surgery?
A provoked VTE may require approximately three months of anticoagulation.

79. When may long-term anticoagulation be required?
Long-term anticoagulation may be required for recurrent unprovoked VTE or VTE associated with active cancer.

80. What is the main role of anticoagulation in pulmonary embolism?
The main role is to prevent further clot propagation and reduce the risk of recurrent embolic events.

81. When may thrombolytic therapy be considered in pulmonary embolism?
Thrombolytic therapy may be considered in patients with massive pulmonary embolism and hemodynamic instability.

82. What systolic blood pressure may indicate hemodynamic instability in massive pulmonary embolism?
A systolic blood pressure below 90 mm Hg may indicate hemodynamic instability.

83. What prolonged drop in systolic blood pressure may indicate hemodynamic instability in pulmonary embolism?
A decrease of at least 40 mm Hg lasting more than 15 minutes may indicate hemodynamic instability.

84. What additional signs may suggest severe hemodynamic compromise in pulmonary embolism?
The need for vasopressor or inotropic support, acute right-heart failure, or shock may indicate severe hemodynamic compromise.

85. What can be considered when thrombolysis is contraindicated or unsuccessful in severe pulmonary embolism?
Catheter-based embolectomy or surgical pulmonary embolectomy may be considered.

86. What supportive treatments may be used in acute pulmonary embolism?
Supportive care may include supplemental oxygen, analgesia, intravenous fluids, and vasopressor therapy.

87. When may an inferior vena cava filter be considered?
An inferior vena cava filter may be considered when anticoagulation is contraindicated or when pulmonary embolism recurs despite adequate anticoagulation.

88. What is the purpose of an inferior vena cava filter?
Its purpose is to trap venous thrombi before they reach the pulmonary circulation.

89. What is an important long-term disadvantage of an inferior vena cava filter?
IVC filters are associated with an increased incidence of recurrent deep venous thrombosis.

90. Why is anticoagulation necessary during ECMO?
Anticoagulation is necessary because blood contacts artificial circuit surfaces that activate coagulation and promote thrombus formation.

91. Which anticoagulant is commonly used as a continuous infusion during ECMO?
Unfractionated heparin is commonly used as a continuous infusion during ECMO.

92. Why is antithrombin important during heparin therapy on ECMO?
Heparin depends on antithrombin to produce its anticoagulant effect.

93. What can happen if a patient on ECMO has antithrombin deficiency?
The patient may appear resistant to heparin because increasing doses fail to produce the expected anticoagulant effect.

94. What findings may suggest inadequate anticoagulation within an ECMO circuit?
Visible clot formation, rising circuit resistance, and increasing premembrane pressures may suggest inadequate anticoagulation.

95. What bedside test has traditionally been used to monitor anticoagulation during ECMO?
The activated clotting time (ACT) has traditionally been used.

96. What ACT ranges have been described as therapeutic targets during ECMO?
Target ranges such as approximately 160 to 180 seconds or 180 to 200 seconds have been described.

97. What additional tests can help assess anticoagulation during ECMO?
Anti-factor Xa activity and antithrombin levels can provide additional information.

98. What is a commonly described therapeutic anti-factor Xa range during ECMO?
A range of approximately 0.3 to 0.7 has been described.

99. What is the major anticoagulation-related complication of ECMO?
Bleeding is the major anticoagulation-related complication of ECMO.

100. Why does intracranial hemorrhage represent a major concern in neonatal ECMO?
Neonates are vulnerable because systemic anticoagulation, altered cerebral blood flow, prematurity, hypoxemia, acidosis, and blood pressure changes can all increase the risk of intracranial bleeding.

Final Thoughts

Anticoagulation is used to prevent clot formation, limit extension of existing thrombi, and reduce the risk of recurrent thromboembolic events. Common agents include unfractionated heparin, low-molecular-weight heparin, direct thrombin inhibitors, warfarin, and direct oral anticoagulants.

Each medication has unique mechanisms, monitoring requirements, adverse effects, and reversal considerations. Anticoagulation is especially important in VTE, pulmonary embolism, and ECMO, where uncontrolled thrombosis can have serious consequences.

Effective therapy requires continuous attention to both sides of the coagulation balance, preventing dangerous clot formation while minimizing the risk of significant bleeding.